Genus PLC (GNS) - Total Assets

Latest as of June 2025: GBX899.00 Million GBX ≈ $109.38K USD

Based on the latest financial reports, Genus PLC (GNS) holds total assets worth GBX899.00 Million GBX (≈ $109.38K USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

Genus PLC - Total Assets Trend (1996–2025)

This chart illustrates how Genus PLC's total assets have evolved over time, based on quarterly financial data. Also see Genus PLC stock valuation for the company's overall valuation and market capitalisation.

Genus PLC - Asset Composition Analysis

Current Asset Composition (June 2025)

Genus PLC's total assets of GBX899.00 Million consist of 28.3% current assets and 71.7% non-current assets. Review GNS liabilities breakdown to assess the company's total debt and financial obligations.

Asset Category Amount (GBX) % of Total Assets
Cash & Equivalents GBX0.00 5.3%
Accounts Receivable GBX109.30 Million 12.2%
Inventory GBX80.90 Million 9.0%
Property, Plant & Equipment GBX0.00 0.0%
Intangible Assets GBX55.30 Million 6.2%
Goodwill GBX102.80 Million 11.4%

Asset Composition Trend (1996–2025)

This chart illustrates how Genus PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See GNS live share price for real-time trading data and today's change.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Genus PLC's current assets represent 28.3% of total assets in 2025, a decrease from 49.3% in 1996.
  • Cash Position: Cash and equivalents constituted 5.3% of total assets in 2025, down from 13.8% in 1996.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 0.0% in 1996.
  • Asset Diversification: The largest asset category is accounts receivable at 12.2% of total assets.

Genus PLC Competitors by Total Assets

Key competitors of Genus PLC based on total assets are shown below.

Company Country Total Assets
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
USA $2.19 Billion
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
USA $11.72 Billion
Tubize-Fin
BR:TUB
Belgium €1.99 Billion
Celldex Therapeutics Inc
NASDAQ:CLDX
USA $511.25 Million
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
USA $452.70 Million
Neuren Pharmaceuticals Ltd
AU:NEU
Australia AU$331.25 Million
NANOBIOTIX S.A. SP.ADR
F:5NRA
Germany €67.76 Million
Savara Inc
NASDAQ:SVRA
USA $192.14 Million

Genus PLC - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.94 1.80 1.72
Quick Ratio 1.32 1.21 1.43
Cash Ratio 0.00 0.00 0.00
Working Capital GBX123.10 Million GBX120.50 Million GBX93.60 Million

Genus PLC - Advanced Valuation Insights

This section examines the relationship between Genus PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.45
Latest Market Cap to Assets Ratio 0.02
Asset Growth Rate (YoY) -12.6%
Total Assets GBX899.00 Million
Market Capitalization $16.90 Million USD

Valuation Analysis

Below Book Valuation: The market values Genus PLC's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Genus PLC's assets decreased by 12.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Genus PLC (1996–2025)

The table below shows the annual total assets of Genus PLC from 1996 to 2025.

Year Total Assets Change
2025-06-30 GBX899.00 Million
≈ $109.38K
-12.63%
2024-06-30 GBX1.03 Billion
≈ $125.19K
+2.12%
2023-06-30 GBX1.01 Billion
≈ $122.58K
-1.02%
2022-06-30 GBX1.02 Billion
≈ $123.85K
+19.61%
2021-06-30 GBX851.00 Million
≈ $103.54K
-0.51%
2020-06-30 GBX855.40 Million
≈ $104.08K
+6.45%
2019-06-30 GBX803.60 Million
≈ $97.77K
+1.82%
2018-06-30 GBX789.20 Million
≈ $96.02K
-1.05%
2017-06-30 GBX797.60 Million
≈ $97.04K
+7.92%
2016-06-30 GBX739.10 Million
≈ $89.93K
+14.71%
2015-06-30 GBX644.30 Million
≈ $78.39K
+10.29%
2014-06-30 GBX584.20 Million
≈ $71.08K
-4.29%
2013-06-30 GBX610.40 Million
≈ $74.27K
+3.77%
2012-06-30 GBX588.20 Million
≈ $71.57K
+8.64%
2011-06-30 GBX541.40 Million
≈ $65.87K
-0.18%
2010-06-30 GBX542.40 Million
≈ $65.99K
+8.94%
2009-06-30 GBX497.90 Million
≈ $60.58K
+14.20%
2008-06-30 GBX436.00 Million
≈ $53.05K
+0.28%
2007-06-30 GBX434.80 Million
≈ $52.90K
-4.71%
2006-06-30 GBX456.30 Million
≈ $55.52K
+44.00%
2006-03-31 GBX316.88 Million
≈ $38.55K
+202.94%
2005-03-31 GBX104.60 Million
≈ $12.73K
+10.09%
2004-03-31 GBX95.01 Million
≈ $11.56K
+32.39%
2003-12-31 GBX71.77 Million
≈ $8.73K
-29.45%
2003-03-31 GBX101.73 Million
≈ $12.38K
+145.07%
2002-12-31 GBX41.51 Million
≈ $5.05K
-56.27%
2002-03-31 GBX94.92 Million
≈ $11.55K
+164.38%
2001-12-31 GBX35.90 Million
≈ $4.37K
-65.48%
2001-03-31 GBX104.00 Million
≈ $12.65K
+0.64%
2000-03-31 GBX103.34 Million
≈ $12.57K
+118.15%
1999-03-31 GBX47.37 Million
≈ $5.76K
+22.64%
1998-03-31 GBX38.63 Million
≈ $4.70K
+5.33%
1997-03-31 GBX36.67 Million
≈ $4.46K
+13.73%
1996-03-31 GBX32.25 Million
≈ $3.92K
--

About Genus PLC

LSE:GNS UK Biotechnology
Market Cap
$16.90 Million
GBX138.94 Billion GBX
Market Cap Rank
#25726 Global
#285 in UK
Share Price
GBX2092.00
Change (1 day)
-1.97%
52-Week Range
GBX1966.00 - GBX3170.00
All Time High
GBX5805.43
About

Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It offers dairy and beef bull semen and embryos under the Genus and Bovec brands; breeding pork and semen, as well as techni… Read more